eligibility_summary
Adults 18–75 with ≥1-year AD (Hanifin–Rajka), EASI ≥16, IGA ≥3, BSA ≥10%, inadequate response to topical therapy/phototherapy, stable emollients ≥7 days, women not pregnant/lactating, contraception. Exclude: confounding dermatoses, abnormal labs, severe/uncontrolled comorbidities, substance abuse, drug allergy, active/recent infections (HBV/HCV/TB/HIV/syphilis, parasitic/skin), recent live vaccine, trial, phototherapy, recent systemic/topical immunosuppressants/biologics, prior OX40 Ab, cancer, transplant.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests BAT6026, a monoclonal antibody (immunotherapy) for moderate–severe atopic dermatitis. BAT6026 targets the OX40 (CD134) costimulatory pathway, it is intended to block OX40–OX40L signaling and/or deplete OX40-positive activated T cells, reducing T-cell activation, survival, and inflammatory cytokines (notably type 2 cytokines such as IL-4 and IL-13). Arms: BAT6026 300 mg Q4W, 600 mg Q4W, or 600 mg Q2W versus placebo (saline). Primary biologic targets: activated OX40-expressing CD4+ T cells (Th2 predominant, also Th1/Th17) and skin-infiltrating effector/memory T cells. Key pathway: OX40–OX40L (TNFRSF4/TNFSF4) costimulation that drives NF-κB–mediated T-cell expansion and survival, goal is to attenuate type 2–driven AD inflammation.